Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Jesper WaldenströmDepartment of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden;

Martti FärkkiläClinic of Gastroenterology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland;

Karolina RembeckDepartment of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden;

Gunnar NorkransDepartment of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden;

Nina LangelandDepartment of Clinical Science, University of Bergen, Bergen, Norway; ;Department of Medicine, Haukeland University Hospital, Bergen, Norway;

Kristine MørchDepartment of Medicine, Haukeland University Hospital, Bergen, Norway;

Court PedersenDepartment of Infectious Diseases, University of Southern Denmark, Odense, Denmark;

Mads Rauning BuhlDepartment of Infectious Diseases, Aarhus University, Aarhus, Denmark;

Urpo NieminenClinic of Gastroenterology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland;

Hannu NuutinenClinic of Gastroenterology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland;

Åsa AlsiöInfektion, Skaraborgs Sjukhus Skövde, Skövde, Sweden;

Lars HolmströmInfektionskliniken, Hallands sjukhus, Halmstad, Sweden;

Rolf JungneliusInfektionskliniken, Södra Älvsborgs Sjukhus, Borås, Sweden;

Katarina LundInfektionskliniken, NÄL, Trollhättan, Sweden;

Anders RubenssonInfektionskliniken, Centralsjukhuset, Karlstad, Sweden

Erik TorellInfektionskliniken, Gävle Sjukhus, Gävle, Sweden

Johan WestinDepartment of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden;

Martin LaggingDepartment of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Correspondence[email protected]

show all

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date